C4M

• Quantifies specific fragments of type IV collagen produced by matrix metalloproteinase activity.
• Reflects basement membrane degradation associated with tissue remodeling.
• Provides a non-invasive measure of extracellular matrix turnover in various pathological conditions.
• Supports monitoring of disease progression and response to therapies targeting extracellular matrix remodeling.
• Applicable in research on diseases characterized by basement membrane disruption, such as rheumatoid arthritis and cancer.
• Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation.
• Complements other biomarkers for a comprehensive assessment of tissue remodeling dynamics.

The C4M biomarker assay measures specific neo-epitope fragments of type IV collagen generated through matrix metalloproteinase activity, serving as an indicator of basement membrane degradation and extracellular matrix remodeling. This non-invasive assay provides insights into pathological tissue remodeling processes, particularly in conditions such as rheumatoid arthritis, cancer, and fibrotic diseases. By quantifying collagen degradation products associated with matrix metalloproteinase activity, the C4M assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tissue remodeling. It serves as a valuable tool in both clinical and research settings for assessing the dynamics of basement membrane and extracellular matrix turnover.

Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.